- T2B Monthly
- Posts
- Remember to sign up for Feb.’s Comm Convo
Remember to sign up for Feb.’s Comm Convo
“Defining Strategic” this Thursday @ 1 p.m. ET
Hi!
This is your reminder that this month’s Comm Convo on ‘defining strategic’ is on Thursday, February 27th @ 1 p.m. ET / 10 a.m. PT / 6 p.m. GMT.
To encourage open, candid conversations, this session won’t be recorded – so the only way to find out what’s said is to join us live on the day.
T2B Pro members can RSVP for free via their Pro account login. Follow the link and enter the promo code to attend for free.
T2B Basic members can buy a ticket for this event for $40.
What can you expect from this session?
Being strategic is one of the most overused phrases in biopharma communications – but what does it actually mean? Let’s join forces to demystify it!
Together, we’ll:
Find out what “being strategic” means in biopharma communications and how it influences corporate decision-making.
Learn practical ways to align communications plans with business objectives and guide organizational direction.
Gain insights into educating stakeholders about the comms function to set clear expectations and drive success.
Explore how to give and receive feedback on strategic thinking to demonstrate growth and impact.
Meet our panelists
Like all T2B events, we’ve carefully selected the most knowledgeable speakers to help us navigate this topic:
Sue Hager, an operating partner and the chief marketing officer on the a16z Bio + Health investing team. She oversees the fund's marketing, branding, and health policy, and her current experience and viewpoint of supporting and facilitating strategic comms make her the perfect panelist for this event.
Abbas Kazimi, the chief business officer at Nimbus Therapeutics, where he also oversees corporate affairs. In his decade+ at Nimbus, he’s seen first-hand the vital role that our function plays in supporting various stages of company growth and the drug development cycle.
Fiona Olivier, who was most recently head of corporate affairs at Sanofi and transitioned to a biotech firm, OSE Immunotherapeutics, only a few months ago. Fiona has been a part of both worlds – global enterprise and small organization – and is right in the thick of looking at how being strategic shows up differently across big pharma and biotech for our profession.
I can’t wait to join Sue, Abbas, and Fiona together with you, the T2B community, to dig into what it really means to be “strategic.” I’m looking forward to seeing what we come up with as a group – maybe we’ll even author a new definition of the word!
Lynnea
P.S: Monthly events like this, plus other amazing networking and engagement opportunities, are included for free as part of the T2B Pro membership.